Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0LRCUN
ADC Name	huAb3v2.9-TX
Synonyms	huAb3v2.9 TX; huAb3v2.9TX Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Small cell lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	1.7
Structure
	3D MOL	2D MOL
Antibody Name	huAb3v2.9		Antibody Info
Antigen Name	CD276 antigen (CD276)		Antigen Info
Payload Name	Undisclosed
Linker Name	huAb3v2.9-TX linker
Combination Type	AbbVie's TX

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	86	%	NCI-H146 cells	Small cell carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	86.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

References

Ref 1	Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.